Radioimmunotherapy Treatment Market

By Drug Type;

Ibritumomab, Tositumomab, Rituximab, Epratuzumab, Lintuzumab, Labetuzumab, Trastuzumab, and Others

By Procedure Type;

Direct Method and Indirect Method

By Disease Indication;

Non-Hodgkin lymphoma, Myeloid Leukemia, Colorectal Cancer, Breast Cancer, Multiple Myeloma, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn762023885 Published Date: June, 2025 Updated Date: July, 2025

Radioimmunotherapy Treatment Market Overview

Radioimmunotherapy Treatment Market (USD Million)

Radioimmunotherapy Treatment Market was valued at USD 932.36 million in the year 2024. The size of this market is expected to increase to USD 1497.16 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Radioimmunotherapy Treatment Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 932.36 Million
Market Size (2031)USD 1497.16 Million
Market ConcentrationMedium
Report Pages321
932.36
2024
1497.16
2031

Major Players

  • DeRoyal
  • Albert David Ltd
  • Braun Melsungen AG
  • Terumo Corporation
  • Connecticut Hypodermics Inc
  • Insulet
  • Septodont
  • Medtronic
  • BD
  • Schott AG
  • Cardinal Health
  • Smiths Medical

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Radioimmunotherapy Treatment Market

Fragmented - Highly competitive market without dominant players


The Radioimmunotherapy Treatment Market is advancing steadily as targeted therapies gain momentum, with over 40% of cancer centers integrating radioimmunotherapy into their treatment protocols. By combining immunologic targeting with radiotherapy, this approach enhances cancer cell destruction while preserving healthy tissue. As a result, the market is benefiting from increasing demand for precision treatments, enabling more controlled and effective cancer management. The rising shift toward integrated therapeutic approaches is creating space for future innovations.

R&D and Technological Growth Driving Momentum
With research investments climbing by 45%, the market is being propelled by breakthroughs in radiopharmaceuticals and antibody conjugation technologies. Scientists are now developing tailored solutions that deliver radiation directly to tumor sites using monoclonal antibodies. This wave of technological advancements is improving both treatment efficiency and patient safety. These innovations are not only improving survival rates but also contributing to a sustainable model for ongoing expansion and development in oncology care.

Surging Demand and Opportunity Creation
Demand for radioimmunotherapy has surged by more than 50%, particularly among specialized treatment institutions aiming for less invasive, more targeted therapies. This rise is directly linked to clinical successes and a transition toward personalized cancer care. These trends offer abundant opportunities for manufacturers and developers to innovate and capture emerging segments. As providers seek high-performance therapeutic options, this treatment modality stands out as a key driver of future growth potential.

Shaping the Future Through Innovation and Expansion
The future outlook for radioimmunotherapy is robust, with development initiatives expanding by over 47% across clinical pipelines. Supportive regulations and increased funding are accelerating the entry of new therapies. Furthermore, the fusion of targeted radiation delivery with immune-based therapies is revolutionizing cancer treatment. These trends underscore the importance of continued innovation, strategic investments, and expanded access to advanced solutions that will define the market’s evolution in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Procedure Type
    3. Market Snapshot, By Disease Indication
    4. Market Snapshot, By Region
  4. Radioimmunotherapy Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Cancer

        2. Development of Novel Radioisotopes

        3. Rising Incidence of Various Cancer Types

        4. Growing Need for Effective Cancer Therapies

      2. Restraints
        1. Rising Incidence of Cancer

        2. Technological Advancements

        3. Increasing Healthcare Expenditure

      3. Opportunities
        1. Market Expansion Trends

        2. Regulatory Developments

        3. Technological Advancements

        4. Strategic Partnerships and Collaborations

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Radioimmunotherapy Treatment Market,By Drug Type, 2021 - 2031 (USD Million)
      1. Ibritumomab
      2. Tositumomab
      3. Rituximab
      4. Epratuzumab
      5. Lintuzumab
      6. Labetuzumab
      7. Trastuzumab
      8. Others
    2. Radioimmunotherapy Treatment Market, By Procedure Type, 2021 - 2031 (USD Million)
      1. Direct Method
      2. Indirect Method
    3. Radioimmunotherapy Treatment Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Non-Hodgkin lymphoma
      2. Myeloid leukemia
      3. Colorectal cancer
      4. Breast Cancer
      5. Multiple Myeloma
      6. Others
    4. Radioimmunotherapy Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. DeRoyal

      2. Albert David Ltd

      3. Braun Melsungen AG

      4. Terumo Corporation

      5. Connecticut Hypodermics Inc

      6. Insulet

      7. Septodont

      8. Medtronic

      9. BD

      10. Schott AG

      11. Cardinal Health

      12. Smiths Medical

  7. Analyst Views
  8. Future Outlook of the Market